Doctor's Profile
  about center
  about ablathem
  our services
  news & events
  contact us

Join our Newsletter to receive our latest news; Insert your email address:
 
Click here to Unsubscribe.
BENEFITS
NON INVASIVE
no port , no seeds , no radiation

EFFECTIVE
precise and definitive necrosis of the targeted area

EARLY FEEDBACK
nadir PSA after only 3 months

QUALITY OF LIFE
minimal side effects

REPEATABLE
if needed at any time during follow-up

ADAPTABLE
to the physician’s and the patient’s therapeutic goals

NO THERAPEUTIC IMPASSE
alternative options still open post Ablatherm

COST EFFECTIVE
24 hours hospitalization

REGULATORY APPROVAL
CE mark january 2000
ABLATHERM:
THE FUTURE IS IN YOUR HANDS

 top

For the first time, a treatment that is :

Adaptable :
to the physician’s and the patient’s therapeutic goals.

Repeatable :
if needed at any time during follow-up.

Not a therapeutic impasse :
alternative options still open post Ablatherm.


Ergonomic control panel :

Powerful software combines the visualization
and the control of the entire treatment process :
The software enables a constant monitoring of the treatment process from the definition of treatment area by ultrasound and the three-dimensional planning of the treatment to the firing phase with a real time monitoring of the transducer position.


Optimization of performance :

The Ablapak :
A single use medical disposable. It contains the Ablasonic liquid that enables the optimal transmission of accoustic energy to the tissue. The circulating liquid is cooled and thus ensures the thermic protection of the rectum.


Indications :

Localized prostate cancer :
   • First choice therapy
   • Salvage therapy for local recurrence after external radiotherapy or radical surgery.

 top

FOCUSED ULTRASOUND
3D IMAGING DYNAMIC FOCUSING
For a safe and efficient treatment :

The bi-plan ultrasound imaging probe enables a precise three-dimensional visualization of the treatment area.
The combination of the essential imaging quality with the strength of the treatment planning software makes the Ablatherm safe and efficient.		 For a safe and precise positioning :

Real time monitoring of the distance between the transducer and the rectal wall (in A mode) associated with the automatic readjustment of the position of the focal point allows for a positioning that is safe and precise.
Furthermore, the physician can choose the length of the lesion from 19 to 24 mm which ensures an adapted treatment.
ABLATHERM HIC PRODUCTIVITY
For a perfect control of the lesion :

The use of the cavitation phenomenon (Ablatherm HIFU Induced Cavitation Technology) allows for a better control of the geometry of the lesion that can be as long as 24 mm. Due to the variable length of the lesion, the AP diameter of the prostate can generally be treated in one session using the same probe.		 For an optimal time of treatment :

All the firing and control phases are automatic which optimizes the treatment of the entire gland (1h30 for 30 cc).

 top

IN THE QUEST FOR EXCELLENCE EVERYBODY FINDS AN ANSWER WITH ABLATHERM
LARGE COHORT OF PATIENTS

559 patients in six sites
European Multicentric Study : 559 patients included in 6 European hospitals with 51 months follow-up.

Results :
Up to 92.1 % negative biopsies and 75 % patients with a nadir PSA lower than 0.4 ng/ml.
Negative biopsy rate (%)
German Study Over 5 Years Our Study Over 7 Years
Biopsy Negative
PSA constant < 1
PSA > 4 		Biopsy Negative
PSA constant < 1
• Click here to view the Study
LONG TERM FOLLOW-UP

Up to 81 Months
Study, A. Gelet et al. : 145 patients with an inclusion PSA lower or equal to 30 ng/ml and up to 81 months follow-up after the Ablatherm treatment.

Results
Up to 84 % follow-up with disease free progression at 5 years with combined biopsy and PSA criteria and actuarial survival curve with a plateau after 18 months for patients with PSA ≤ 10 and Gleason score ≤ 6.

PRESERVED QUALITY OF LIFE
Low Acute Morbidity
and No Chronic Toxicity

Confirmed by the study in Munich		 The Ablatherm offers an actual treatment strategy for sexual function preservation, without oncologic compromise due to the unique possibility of retreatment.
Death (intra and post-op)
Fistula
Rectal wall burn
Hemorrhoidal pain
Stress Incontinence Grade I (mean 27 days)
Stress Incontinence Grade II (mean 32 days)
Urge incontinence
UTIs
Significant hematuria		 0%
0%
0%
1%
9%
2%
0%
13%
0%

 top
Home  |  Doctor's Profile  |  About Center  |  About Ablatherm  |  Services  |  News & Events  |  Contact Us
Copyright 2006, Designed and Developed by Pixels-Lab